發佈日期︰2021-12-09 │ 發佈人︰後台管理員
Expanding access to long-acting antipsychotics in low-income and middle-income countries
At the 23rd meeting of WHO's Expert Committee on Selection and Use of Essential Medicines, paliperidone palmitate 1-monthly formulation was added to WHO's Essential Medicines List. A square box symbol, next to paliperidone palmitate, indicates risperidone long-acting injection as a therapeutic alternative.
Action is now urgently required to increase affordability and appropriate use of long-acting injections in clinical practice.
Pursuant to the strategy outlined by WHO and The Lancet's Commission on Essential Medicines Policies, long-acting injections should be included in the list of patented essential medicines to undergo public health-oriented patent pooling. This measure would support generic manufacturing, which is a valuable public health approach to improve accessibility of otherwise expensive treatments (e.g. antiretroviral medicines) in LMICs.
link
source：The Lancet Psychiatry